Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Antibacterial envelope is shown to reduce major device infection rates by more than 90 percent

TYRX : 14 May, 2013  (Company News)
Use of TYRX's AIGISRx Antibacterial Envelope is shown to reduce major infection rates by more than 90 percent in patients undergoing Cardiovascular Implantable Electronic Device (CIED) replacement procedures compared to similar high-risk cohorts, according to the CITADEL & CENTURION clinical study results presented at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions.


CITADEL/CENTURION is a prospective, multicentre clinical study to evaluate the major device infection and mechanical complication rates in the 12 months after implantation, in patients at high risk for CIED infection who have their CIED implanted with an AIGISRx Antibacterial Envelope. Study patients were enrolled at 55 US centres, and were at high-risk for infection because they were undergoing a CIED replacement procedure with an implantable cardioverter-defibrillator (ICD), (CITADEL), or a cardiac resynchronization therapy (CRT) device (CENTURION).



The results from a planned interim analysis of the primary endpoints for the first 1000 eligible patients after 90 days of follow up were presented by Dr Charles Henrikson, the Chief of Electrophysiology at the Oregon Health Sciences University.



Key study findings include:



The CITADEL / CENTURION cohort at 90 days of follow-up had 95 percent fewer major CIED infections than the pre-defined published control cohort of 533
ICD and CRT replacement procedures (Gould et al. JAMA 2006, 295(16); 1907-1911) which had a major CIED infection rate of 1.88 percent at a mean follow-up of 81 days (0.1 percent vs. 1.88 percent; P<0.001).



The CITADEL / CENTURION cohort at 90 days of follow-up had 94 percent fewer major infections than the 45-day major infection rate of 1.7 percent reported for the cohort of 1081
ICD/CRT replacement procedures in the Ontario ICD Database (Krahn et al. Circulation Arrhythmia and Electrophysiology 2011 4(2) 136-42 (0.1 percent vs. 1.7 percent; P<0.001).



There was 1 major infection (0.1 percent), the primary efficacy endpoint of the study, after 90 days of follow-up. There were 11 minor infections (limited to the incision and skin) (1.1 percent).



The incidence of the most common mechanical complication, major hematomas (1.5 percent), was not significantly different than the pre-defined control cohort (2.3 percent; P = NS).



There were no unanticipated serious AIGISRx-related adverse events. There were 20 (2 percent) deaths, none related to the AIGISRx.



"CIED infections are increasing in frequency, are associated with substantial morbidity, mortality, and cost, and present significant challenges to patients and for the physicians who provide care for them," stated Charles Henrikson, MD, FHRS, Oregon Health Sciences University, Portland, Oregon. "The CITADEL & CENTURION are large prospective studies enrolling patients at community, academic, and VA medical centers which will provide us with useful clinical information on the use of the AIGISRx Envelope in a variety of patients who are at high risk for CIED infection."


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo